https://www.selleckchem.com/pr....oducts/acalabrutinib
Portal hypertension (PHT) and its complications in children are thought to be distinct from adult PHT in several areas, including the underlying bio-physiology of a child in which PHT develops, but also because of the pediatric-specific etiologies that drive disease progression. And yet pharmacologic approaches to PHT in children are mainly based on adult data, modified for pediatric practice. This reality has been driven by a lack of data specific to children. The authors discuss current therapeutic approaches to PHT in children,
Like
Comment
Share
